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Abstract
We review the evidence and identify limitations of the current literature on the effectiveness of 
brief interventions (≤5 intervention sessions) on illicit drug use, treatment enrollment/retention, 
and pregnancy outcomes among pregnant and postpartum women; and consider this evidence in 
the context of the broader brief intervention literature. Among 4 published studies identified via 
systematic review and meeting a priori quality criteria, we found limited, yet promising evidence 
of the benefit of brief interventions to reduce illicit drug use among postpartum women. Two of 
the 4 randomized controlled trials tested similar computer-delivered single-session interventions; 
both demonstrate effects on postpartum drug use. Neither of the 2 randomized controlled trials that 
assessed treatment use found differences between intervention and control groups. Studies 
examining brief interventions for smoking and alcohol use among pregnant women, and for illicit 
drug use in the general adult population, have shown small but statistically significant results of 
the effectiveness of such interventions. Larger studies, those that examine the effect of assessment 
alone on illicit drug use, and those that use technology-delivered brief interventions are needed to 
assess the effectiveness of brief interventions for drug use in the peripartum period.
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Illicit drug use during pregnancy has been associated with a range of adverse neonatal 
outcomes, including intrauterine growth restriction, preterm birth and lower birthweight, 
neonatal abstinence syndrome, and neurocognitive delays and impairment.1 Illicit drug use 
during the postpartum period is associated with increased risk of child neglect,2 violence 
exposure,3 physical abuse,4 externalizing behavioral problems,5 and substance use in 
adolescence.6 Despite the frequency with which women reduce or quit drug use during 
pregnancy,7 nationally representative data show that4.4% of pregnant women reported use of 
illicit drugs (marijuana/hashish, cocaine [including crack], heroin, hallucinogens, inhalants, 
or prescription-type psychotherapeutics used nonmedically) in the past month.8
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Candidate treatments for illicit drug use during pregnancy and the post-partum period 
include counseling and specialized maintenance treatment for opioid dependence. However, 
over 50% of illicit drug users neither seek nor receive treatment,8 making proactive 
identification necessary. Screening, brief intervention, and referral to treatment (SBIRT) is 
an evidence-based, proactive, and quick way for healthcare providers to identify, counsel, 
and refer patients to receive additional counseling and treatment for a behavioral health 
condition, usually substance abuse.
Among pregnant women, brief motivational interventions have been shown to modestly 
improve smoking cessation rates9 and alcohol abstinence.10 However, few studies have 
examined the effects of brief interventions for illicit drug use during pregnancy or the 
postpartum period. Therefore, we reviewed the available evidence and identified potential 
ways to improve future studies on the effectiveness of brief interventions on illicit drug use, 
treatment enrollment/retention, and pregnancy outcomes among pregnant and postpartum 
women.
Literature search
We searched the PubMed, Embase, and PsychInfo databases for research articles using 
keywords and MeSH terms associated with illicit drug use, related interventions, and 
pregnancy and postpartum. In 2001, the Institute of Medicine’s Committee on the Quality of 
Health Care in America issued a call for screening for health risk behaviors, including 
substance use, in tandem with appropriate assessment and referral activities, and cited the 
SBIRT model as a promising practice.11 Thus, we limited the search to articles published 
after the release of this Institute of Medicine report, between Jan. 1, 2002, and Sept. 20, 
2013. We examined reference lists from the studies found and consulted with authors of 
peer-reviewed published papers on illicit drug use among pregnant and postpartum women 
to identify relevant articles published before 2002.
Eligibility criteria for this systematic review were based on intervention type, study 
population, design, and outcomes described below. In line with the substance abuse and 
mental health services administration definition, we defined brief interventions as consisting 
of 1–5 sessions lasting 5 minutes to 1 hour each, and excluded studies examining more 
intensive interventions. We included only studies examining brief interventions among 
pregnant women or women ≤1 year postpartum with the intended goal of reducing or 
abstaining from drug use, enrolling and retaining women in specialized drug treatment 
programs, and improving pregnancy and/or infant outcomes. We only included studies with 
a control group not offered the intervention during the study period.
One author (Y.L.H.) extracted data from the studies included in the review into a 
standardized Table and a second author (S.L.F.) checked the extracted data for accuracy. The 
authors assessed quality of each study by adapting a published set of criteria developed and 
piloted by the US preventive services task force.12 A grade was given for research design (I 
= randomized controlled trials (RCTs); II-1 = well-designed controlled trial without 
randomization; and II-2 = well-designed cohort or case-control study) and internal validity 
(good, fair, or poor). For RCTs, internal validity was based on the 7 following criteria: 
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adequate randomization, low attrition and high adherence, low differential or total loss to 
follow-up, clear definition of intervention, high reliability and validity of exposure and 
outcome measures, important outcomes considered, and an intent-to-treat analysis. “Good” 
studies met ≥6 of the 7 criteria, “fair” studies met <6 of the criteria, but did not have a 
methodologic flaw that invalidated the study’s findings, and “poor” studies contained a 
methodologic flaw that invalidated the study’s findings.12
Our search found 3792 unique articles (Figure). Two authors (S.L.F. and Y.L.H.) reviewed 
titles and abstracts and determined that 114 articles were potentially eligible for inclusion in 
the review. Separately, both authors reviewed the 114 articles in full and agreed that 3 
articles met all inclusion criteria. Three additional articles published before 2002 were found 
after reviewing reference lists of the 114 articles and consulting with experts in the field. Of 
the 3 additional articles, only 1 met all inclusion criteria. Therefore, a total of 4 articles (1 
published before and 3 published after 2002) met our inclusion criteria and were included in 
this systematic review.
Brief interventions for illicit drug use among pregnant and postpartum 
women
We identified 4 RCTs published between 1996 and 2013 ranging in sample size from 71 to 
179 women (Table 1).13–16 One RCT recruited postpartum14 women enrolled in outpatient 
treatment programs, and 3 RCTs enrolled pregnant13 and postpartum women15,16 through 
prenatal clinics or during their delivery hospitalizations. Outcomes examined included drug 
use and specialized treatment enrollment or retention; no studies examined pregnancy or 
infant outcomes (Table 2). Three studies were considered “good” quality,14–16 and 1 was 
“fair” quality.13
Two “good” quality RCTs10,11 were conducted to assess the effectiveness of a computerized 
single-session intervention for illicit drug use among postpartum women enrolled during 
their delivery hospitalization. Both RCTs used a brief computerized intervention 
administered via laptop or tablet computer and based on motivational interviewing 
techniques. The more recently published RCT, a replication of the 2007 study, enrolled at 
their delivery hospitalization 143 women who self-reported illicit drug use in the 3 months 
before pregnancy and met eligibility criteria. All women received a 30-minute assessment 
prerandomization. Based on self-reported illicit drug use before pregnancy, women were 
randomized to computerized brief intervention (n = 72) or an inactive control condition (n = 
71). Intervention components included eliciting the participant’s thoughts and perceived 
advantages of change; providing normed feedback; and goal-setting. The 2 primary 
outcomes were 7-day point prevalence abstinence from illicit drugs based on self-report and 
negative toxicology screen at 3 and 6 months, and self-reported number of substance-using 
days in the last 90 days. At the 3-month follow-up, the authors found a statistically higher 7-
day point-prevalence of abstinence in the intervention compared with the control arm(26.4% 
vs 9.9%; odds ratio [OR], 3.3; 95% confidence interval [CI], 1.3−8.4; P = .01); median 
number of substance-using days showed a positive trend(25.6 vs 51.4 days; P = .06), but was 
not significant. At the 6-month follow-up, neither the self-report of 7-day point prevalence in 
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the intervention and control groups (13.9% and 9.9%, respectively; OR, 1.5; 95% CI, 
0.5−4.1) nor the median number of substance-using days (31.6 days and 77.2 days, 
respectively; P = .21) differed significantly. However, based on hair sample results, the 
intervention group had 4.8 times greater odds of drug abstinence at 6 months compared with 
the control group (P = .02).
In the initial and smaller of these 2 RCTs, also of “good” quality, the authors enrolled 107 
postpartum women ≥18 years who self-reported illicit drug use in the month before 
pregnancy.15 Women were randomized into assessment only (n = 52) or assessment plus 
brief intervention (n = 55) conditions. During their delivery hospitalization, all women 
completed a 45-minute assessment using a laptop with integrated touchscreen and 
headphones. Women in the assessment plus intervention arm also received a 20-minute, 
single-session, computer-based motivational intervention that elicited the participant’s 
thoughts and perceived advantages of change, provided normed feedback, and offered goal-
setting; this intervention and that from the more recent trial described previously differed 
moderately (eg, the more recent intervention referred specifically to the type of drug used, 
rather than only to “drugs” generically, and presented the content differently for those who 
reported being ready to change or having already done so). Outcomes assessed at 4 months 
postbaseline included drug abstinence and frequency of drug use measured by self-report 
using the Alcohol, Smoking, and Substance Involvement Screening Test questionnaire and a 
urine toxicology test. Women in the assessment plus intervention arm self-reported less use 
of any drugs combined (P = .04) and of drugs other than marijuana (P = .03), but effects on 
marijuana use alone failed to reach statistical significance. Group differences for 
dichotomized outcomes (either urine drug test results alone or toxicology-confirmed self-
reports of no vs any use) in the intervention and control arms were of similar magnitude 
(abstinence from any drug: 33% and 16%, respectively; OR, 2.5; 95% CI,0.6−10.4) but were 
not statistically significant (P = .09).
In a “good” quality RCT conducted by Mullins et al,14 the authors enrolled 71 women from 
a 12-month outpatient comprehensive treatment program. Women enrolled were 27-years-
old on average, and varied by race/ethnicity and primary drug of use. Women randomly 
assigned to the motivational interviewing (MI) arm (n = 35) received 3 individual 1-hour MI 
sessions at baseline, at 1 week and 2 months postbaseline. Women in the control arm (n 36) 
watched educational videos on substance abuse at baseline and 1 week postbaseline, and 
received a 1-hour home visit focused on support and case management at 2 months 
postbaseline. The primary goal of the intervention was treatment retention and engagement 
in a comprehensive drug treatment program as measured by the proportion of group sessions 
attended. Drug use was also tested weekly at random using urine toxicology screens. Neither 
the mean proportion of group sessions attended (P = .56) nor the mean proportion of 
negative urine screens (P = .55) differed between the intervention and control arms.
The “fair” quality RCT conducted by Alemi et al13 recruited 179 pregnant women in their 
third trimester who had used or were using cocaine during or immediately before pregnancy. 
Women ranged in age from 18 to 43 years, 92% were African American, and all were 
Medicaid recipients. Women were randomly assigned to either the intervention (n = 92) or 
control (n = 87) arm. The intervention consisted of computerized services accessed through 
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the participant’s telephone, such as health education, access to pediatric and prenatal 
providers, patient testimonials, and weekly prayers to patients who self-selected to receive 
them. The authors did not examine the individual effects of separate components of the 
intervention. In addition, prenatal or pediatric nurses and drug counselors reviewed patients’ 
records and used the voice mail service to proactively contact the patients about their care. 
The control group had similar access to drug treatment services, but not to computerized 
services; both groups received regular prenatal care. The primary outcomes assessed were 
drug treatment use and changes in drug and alcohol use measured by the addiction severity 
index between baseline and 6 months’ postpartum. Specialized drug treatment use and 
changes in drug and alcohol use did not differ significantly by study arm. Both the control 
and intervention groups self-reported less drug and alcohol use from baseline to 6 months’ 
postpartum, but between-group differences were not statistically significant. Therefore, 
addition of the computerized services did not improve rates of specialized drug treatment 
nor reduce drug and alcohol use more than access to drug treatment services alone.
Considerations in evaluating brief intervention trials
There is growing evidence that mere participation in a study and/or an extended baseline 
assessment may themselves act as a form of brief intervention. For instance, in a randomized 
trial of cognitive-behavioral therapy for alcohol-dependent women, Epstein et al17 found 
that each pretreatment study procedure (eg, telephone screen, baseline evaluation) was 
associated with reductions in drinking, such that 44% of participants were abstinent before 
treatment began. Similarly, in a secondary analysis of data from an RCT among postpartum 
women,18 Ondersma et al19 showed that change in substance use after baseline assessment 
but before receiving the intervention was greater than the change in substance use following 
the intervention. Similar effects have been shown in other studies, including those randomly 
assigning participants to screening vs assessment only conditions.20 The effect of 
assessment on illicit drug use must be more fully examined in future research. For example, 
3-arm designs (screen only, screen+assessment, and screen+assessment+brief intervention) 
could be considered as a standard for brief intervention research.21
In addition, the small effects of brief interventions and the percentage of women who quit 
using substances spontaneously, also have implications for study power. An effect size of d 
= .20 (one-fifth of a standard deviation difference in the intervention and control groups), for 
example, may be large enough to justify implementation of brief interventions for drug use 
during pregnancy. Although observed effects in 2 trials reviewed here were negligible, 
Ondersma et al15 failed to reach statistical significance for dichotomous urine toxicology-
confirmed drug use despite effect sizes in the moderate range. Given this expectation of 
small effect sizes, larger RCTs are needed.
Potential benefits of technology-delivered interventions
Three of the 4 RCTs used technology-delivered interventions without therapist or counselor 
contact,13,15,16 with 2 finding positive results.15,16 A number of systematic reviews and 
metaanalyses of studies on nonpregnant adults suggest that these approaches have promise 
for reducing substance use.22–24 For example, Moore et al22 identified 11 randomized trials 
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of sufficient quality for inclusion in their review, and found that computer-delivered 
interventions led to greater knowledge, higher motivation, greater retention in treatment, and 
less drug use compared with treatment as usual. Two metaanalyses support these results.23,24 
Portnoy et al23 found a mean effect size of d = .24 (P < .001) for computer-delivered 
interventions for reducing substance use (alcohol and/or other drugs) compared with various 
control conditions (eg, assessment only, education only, time-matched irrelevant 
interventions, or printed or face-to-face brief versions of the intervention). Rooke et al24 
found a statistically significant mean effect of d = 0.26 for computer-delivered in terventions 
for alcohol use compared with assessment only, placebo, and treatment-as-usual. Such 
findings suggest that computer-delivered brief interventions may be an important component 
of public health responses to substance abuse, particularly given substantial challenges in 
implementing person-delivered brief interventions.25,26 More research is needed to 
understand how technology-delivered interventions perform among pregnant women.
Interventions among pregnant women
Evaluations of the Early Start program,27–29 a brief intervention for substance use among 
prenatal care patients, showed positive results on drug abstinence, pregnancy outcomes, and 
cost savings, although the control groups included women who refused the intervention. 
Other investigators have examined interventions to increase specialized drug treatment or 
drug abstinence among pregnant women. For example, Winhusen et al18 examined the effect 
of an MI intervention, which did not meet substance abuse and mental health services 
administration criteria for brief intervention, and showed no intervention effect on pregnant 
women’s use of specialized drug treatment or self-reported drug use; however, subsequent 
analysis of the data showed marked pre-treatment change in both the intervention and 
control groups.19 Another study showed no statistical difference in self-reported drug use by 
drug use support group attendance, yet found lower delivery costs for women attending the 
support group.30
Brief interventions for other substances and among other populations
A more extensive set of literature exists on brief interventions for smoking9,31 and alcohol 
use10 among pregnant women, as well as for drug use among the general adult population.32 
In a systematic literature review on smoking cessation interventions for pregnant women, 
brief MI resulted in a 5% reduction in smoking among pregnant women compared with 
treatment as usual and showed positive effects on birthweight and gestational age at birth.9 
Brief interventions for alcohol use among pregnant women, ranging from 10 minutes of 
brief counseling with self-help material to a 1-hour MI with reinforcement at prenatal care 
visits, improved alcohol abstinence during pregnancy; relative risks and odds ratios ranged 
from 1.1 to5.4, about half of which reached statistical significance.10 Within the general 
adult population, when compared with no intervention, brief interventions have been 
effective in reducing drug and alcohol use for up to 12 months post-intervention, but show 
no effect after 12 months.32 However, brief MI for drug use among the general adult 
population showed limited effectiveness or was no more effective when compared with 
assessment and feedback, treatment as usual, or other active interventions. It is unclear how 
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these findings translate to pregnant and postpartum illicit drug-using women, but the 
available evidence is promising.
Comment
We found 4 RCTs examining brief interventions for illicit drug use in pregnant and 
postpartum women.13–16 Two RCTs using computerized brief interventions for drug use 
among post-partum women reduced drug use and increased abstinence among women who 
used illicit drugs before pregnancy. Effects across both studies were of similar magnitude 
(ranging from small to moderate, or one-fifth to one-half of a standard deviation difference 
in the intervention and control groups) and favored the intervention condition. However, for 
specialized treatment use, neither of the 2 RCTs examining brief interventions to increase 
rates of specialized treatment use found an effect.14,15
The brief interventions reviewed here differed with respect to the population of women 
(pregnant or postpartum), number of brief intervention sessions, mode of delivery, provider, 
venue and outcomes of interest, making comparisons and generalized statements on the 
effectiveness of brief interventions difficult. For example, participants in the Mullins et al14 
trial were recruited from a substance abuse treatment program, whereas Ondersma et al,15 
Ondersma et al,16 and Alemi et al13 recruited nontreatment seeking women from medical 
settings. There is some evidence that brief interventions can be helpful adjuncts to traditional 
treatment among adult populations, particularly as precursors designed to facilitate 
engagement.33,34 However, their biggest potential public health impact may be among 
persons with unhealthy levels of substance use who do not seek treatment. Most brief 
intervention research involves proactively recruiting participants from health care settings. 
The Alemi et al,13 Ondersma et al,15 and Ondersma et al16 trials are consistent with this 
model. In addition, the SBIRT model promoted by SAMHSA and others was not applied 
strictly in the studies reviewed here. The intervention used by Mullins et al14 was largely 
informed by MI principles,35 with greater interactivity and use of higher-level clinical skills 
than the SBIRT model. RCTs by Ondersma et al15 were similarly informed by MI 
principles, but relied exclusively on technology. In contrast, Alemi et al13 used a telephone-
based combination of support, tailored messaging, and reminders.
In summary, 2 of the 4 studies identified that used a computerized brief intervention for 
postpartum women showed some evidence of the superiority of brief interventions for drug 
use reduction or abstinence compared to assessment alone or treatment as usual, although 
effects waned over time. The larger body of evidence on brief interventions for smoking and 
alcohol use among pregnant women, and for illicit drug use in the general adult population, 
are promising. Even with small, short-lived effects experienced during the prenatal and 
postpartum period, brief interventions for pregnant and post-partum women may result in 
improved maternal and infant outcomes. Larger studies, those that examine the effect of 
assessment alone on illicit drug use, and those that use technology-delivered brief 
interventions are needed to assess the effectiveness of brief interventions for drug use in the 
peripartum period.■
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FIGURE. 
Published articles identified, reviewed and included in review.
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